Articles On Imugene (ASX:IMU)

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin By Tim Boreham ASX code: ((ALA)) Shares on issue: 1,050,775,660 Market cap: $157.6m...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin World Overnight SPI Overnight 7948.00 – 43.00 – 0.54% S&P ASX 200 8027.00...

Highlights Imugene ended the June quarter with over AU$93 million in cash and equivalents, supporting operations through late 2025. The company is actively recruiting for three Phase 1/1b clinical trials across multiple countries. The...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The S&P/ASX 200 Index (ASX: XJO) is up 2.5% and in new all-time high territory as we near the end of the second trading week of FY 2025. But some ASX shares have already done much better. Now, two weeks is only a small snapshot for thes...

If you're building an income portfolio, then it could be worth looking at the ASX 200 dividend stocks named below. Here's why they could be good options for income investors this month: Cedar Woods Properties Limited (ASX: CWP) Morgans th...

There's an ASX dividend stock on the market right now that, until very recently, was yielding close to 5%. This particular ASX 200 blue chip has rallied significantly over the past few weeks, which has now pushed down its dividend yield clo...

Telstra Group Ltd (ASX: TLS) stock is regularly viewed as an appealing ASX dividend share to own. This could be a compelling time to consider the company for its passive income and dividend potential. Businesses that are able to deliver...

It was a sobering Wednesday session for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares today. After recording a strong gain yesterday, investors appear to hav...

Imugene has dosed its first of 10 Australian patients with its potent “VAXINIA” therapy as part of its phase-one bile tract cancer trial being conducted at St Vincent’s Hospital in Melbourne.

The S&P 500 Index (SP: .INX) and Nasdaq Composite Index (NASDAQ: .IXIC) reached new all-time highs on Wall Street last night. It should be a cause for celebration. If only the record weren't accompanied by a more sinister number crack...

The market is having a bit of a subdued session on Wednesday, but that isn't stopping one ASX robotics stock from storming higher again. At the time of writing, the FBR Ltd (ASX: FBR) share price is up 19% to 5.6 cents. This means that its...

The ASX is down 0.3% to 7,807 points heading into lunchtime trade. Telecommunications is the only sector in the green up 0.9%. This is on the back of Telstra’s pricing announcement released yesterday. All other sectors are in the red wit...

Highlights The first patient in the Phase 1 bile tract cancer trial has been dosed. The trial is expected to enrol 10 patients with bile tract cancer. The sixth high dose cohort of both arms of the Phase 1 MAST monotherapy dose escala...

The market may have run out of steam on Wednesday, but not all ASX shares are falling. Two that are catching the eye of investors and roaring higher this morning are listed below. Here's why investors have been buying their shares today: D...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Imugene has confirmed the delivery of its first “onCARlytics” combination therapy dose to a bile duct cancer patient in the initial phase of a world-first trial at the City of Hope medical centre in the US.

Highlights The first patient has received treatment under the intravenous (IV) infusion combination arm of the Phase 1 onCARlytics trial. The trial aims to enrol nearly 40-45 patients with advanced solid cancers that have spread. Prel...

Imugene Limited (ASX: IMU), has dosed the first patient in the phase 1 clinical trial known as OASIS, which is testing its oncolytic virotherapy drug. The clinical trial is targeting adult patients with advanced or metastatic solid tumou...

The ASX200 is set to fall today, influenced by a mixed US market performance on Friday, which itself was shaped by questions about the long-term viability of the AI-driven rally, and whether the US economy was moderating. At 8.45 am AEST...

Overseas markets rallied in May on lower bond yields and stabilising inflation prints, but the Australian market couldn't sustain the early May up-swing, weighed down by a surprisingly high April CPI reading and some negative earnings updat...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Special Report: A recent lunch put together in Sydney by Jane Morgan Management and Éthica Capital saw a number of the ASX’s most innovative biotech and tech companies present and pitch to an audience of potential investors on the lookout f...

Investors got the chance to get up close and personal with ASX technology and biotech companies in Sydney recently at the JMM & Ethica Capital Innovation & Investment Insights Lunch. Featuring quick ‘stand up and pitch your story’ s...

Highlights Under the Phase 1 MAST trial high cohort dose, dosing of first patients has been concluded. Bile tract cancer expansion study opened. Dosing commenced in the OnCARlytics (CF33-CD19) trial. Imugene joined hands with Kincell...

ASX Health sector was in correction territory in April Why is the health sector different from other sectors? We look at the best performing ASX health stocks for the month   The S&P/ASX 200 Health Care [XHJ] had a soft month in April...

S&P/ASX 200 Health Care (ASX: XHJ) shares are up 0.44% on Tuesday while the ASX 200 is up 0.23%. But these three ASX healthcare shares are knocking it out of the park on this otherwise lacklustre day. Here's why. Paradigm Bio...

Pointsbet Holdings Ltd (ASX: PBH) shares are having a very tough session on Tuesday. In morning trade, the sports betting company's shares crashed as much as 45% to 45.5 cents. The company's shares have recovered a touch since then but rema...

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

There have been a couple of big moves in the betting industry on Wednesday following the release of quarterly updates. Let's dig a little deeper into these releases now and see what's getting investors excited: Bluebet Holdings Ltd (ASX: B...

If you're the type of investor that likes high risk-high reward investments, then read on. That's because a leading broker is tipping an ASX biotech stock to almost double in value over the next 12 months. The company in question is Imugene...

Highlights Imugene's partnership with Kincell Bio is aimed at accelerating the development of innovative immunotherapies. Sale of Imugene's North Carolina facility to Kincell Bio would streamline operations and reduce costs. Collabora...

The ASX staged a relief rally on Monday Gold, oil stocks struggled after tensions in the Middle East eased The focus has now shifted from Middle East tensions to company earnings   The ASX put on a relief rally after its -3% loss last wee...

After shedding nearly double what futures had predicted, the ASX200 closed the day 1.8 per cent down. At one stage the ASX was on track for its worst day in 13 months and at the close, real estate, consumer stocks and mining were all lickin...

Australian anti-cancer company Imugene has stamped a strategic manufacturing deal with Kincell Bio, with the latter agreeing to purchase the company’s North Carolina facility for US$6 million (AU$9.34 million).

Highlights The strategic manufacturing and process development collaboration involves the sale of IMU's CGMP manufacturing facility in North Carolina to Kincell. Kincell will acquire the facility for up to US$6 million in upfront and m...

ASX-listed med-tech company Imugene has launched a pivotal expansion study targeting patients with bile tract cancer following encouraging results from its Metastatic Advanced Solid Tumours trial.

There’s no surprises on market today, the ASX200 has been down around half a per cent – on par with the morning’s predictions. The Energy and Materials sectors have been showing resilience, energy’s up about 0.4% and mining stocks by abo...

Atomo announces more purchase orders for HIV Self-Tests Actinogen says first patient was treated in Alzheimer’s disease study Imugene has opened enrolment for expansion study in solid tumours   Atomo sells more HIV self-test kits Atomo Di...

Highlights Bile tract cancer expansion study opens after the completion of the high dose cohort in the MAST trial. This new trial aims to enrol 10 patients with bile tract cancers, specifically cholangiocarcinoma. Interim findings fro...

Cancer immunotherapy company Imugene Ltd (ASX: IMU) will be expanding its trial for the use of CF33-hNIS (VAXINIA) to treat gastrointestinal cancers – including bile tract cancer (also known as (cholangiocarcinoma) – and is now enrolling te...

It's been a decent week for the S&P/ASX 200 Index (ASX: XJO). Since last Thursday, the ASX 200 has gained a healthy 1.05%. But that's nothing compared to the gains of the Liontown Resources Ltd (ASX: LTR) share price. Liontown shares ha...

If you're not averse to investing in the mining sector and want big returns for your portfolio, then read on. That's because analysts at Bell Potter have just put buy ratings on two ASX 300 mining stocks and are tipping potential upside of...

Highlights IMU’s CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx to showcased at the American Association for Cancer Research (AACR) Annual Meeting. The oncolytic virus CF33-hNIS (VAXINIA), either alone or combined...

If you owned S&P/ASX 200 Index (ASX: XJO) lithium stocks in 2021 and 2022, you likely enjoyed some outsized share price gains at the time. That period saw a massive increase in lithium demand amid strong growth in global battery market...

If you're in the market for some new ASX 200 shares in April, then it could be worth listening to what analysts at Bell Potter are saying. That's because they have just revealed their favoured picks for the month ahead. Two on its list th...

Australian anti-cancer company Imugene has received a patent to protect its unique cancer treatment in China – the largest and most lucrative pharmaceutical market in Asia.

It was a happy Thursday for the S&P/ASX 200 Index (ASX: XJO) and most ASX shares today, with investors shaking off the midweek blues that we saw yesterday. By the end of trading this sessi...